Sequencing antibody-drug conjugates in ER+, HER2-low breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests different sequences of antibody-drug conjugates (a type of targeted chemotherapy) for people with ER-positive, HER2-low or ultra-low metastatic breast cancer that has stopped responding to hormone therapy and has progressed on Enhertu. You must have had 1–4 prior chemotherapies for metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer that is estrogen or progesterone receptor positive (ER+ or PR+) and is HER2-low or ultra-low.
- Your cancer must have grown despite hormone therapy, and you must have taken a CDK4/6 inhibitor (like Ibrance) before.
- You must have received between 1 and 4 prior chemotherapy treatments for metastatic disease. Prior antibody-drug conjugate (ADC) therapy and PARP inhibitor therapy each count as one line.
- You must have received Enhertu (T-DXd) before and stopped it either because it stopped working or caused intolerable side effects.
- You must have measurable disease by a CT or MRI, or bone-only disease with a lytic (destroyed) lesion. Blastic (dense) bone lesions alone are not allowed.
- You must be 18 or older, have adequate organ and blood cell counts, and if applicable, use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two targeted therapies, sacituzumab govitecan and trastuzumab deruxtecan, to see which works better for people with HER2-low or HER2-ultralow metastatic breast cancer. The goal is to find the best treatment order to help control the cancer.
This study tests a drug called sacituzumab govitecan (a type of antibody-drug conjugate that targets cancer cells) as the first treatment for people with advanced triple-negative breast cancer that has not been treated before. The goal is to see if it can help shrink or control the cancer.
This trial tests whether a different chemotherapy drug, called sacituzumab govitecan (SG), can help people with ER+/HER2-low metastatic breast cancer who have already been treated with trastuzumab deruxtecan (T-DXd). It also looks at genetic markers in your tumor to predict who might benefit from SG.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This trial compares two antibody-drug conjugates (targeted cancer-killing drugs) given one after the other to see if they work well for triple-negative breast cancer with low HER2. It aims to provide a new treatment option that may slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.